SUMMARY. In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the ItalianSpanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (41/289) Child-Pugh class A6, 24% (70/289) with varices and 42% (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49%, (58% in F3, 45% in F4, 61% in relapsers, 51% in partial, 38% in null responders, and 72% in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8% (negative predictive value = 92%). Death occurred in 3 (0.8%) patients, while decompensation and infections were observed in 2.9% and 11%, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log 10 -decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/lL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.
INTRODUCTION
Hepatitis C virus -infected patients with advanced fibrosis and cirrhosis still represent a therapeutic challenge in the era of direct acting antiviral agents (DAAs) because of lower SVR rates and poorer tolerability of therapy [1] [2] [3] [4] [5] [6] . Nevertheless, a clear benefit in treating cirrhotic patients exists. In many cases, the urgency to treat their disease before they reach the decompensated stage (i.e. when IFNbased antiviral therapies become contraindicated), is still an unmet clinical need. In this rapidly changing field, safer and more efficacious therapies are emerging, either with or without IFN [7] [8] [9] [10] [11] [12] . Nevertheless, in a very large number of countries worldwide, first-generation protease inhibitors (PIs), combined with the IFN-based regimen, remain the only available option for these patients. To date, Boceprevir (BOC) has been approved and marketed in 67 countries (only 28 in 2013 and 1 in 2014) while it has been approved, but not marketed yet in 14 other countries. As a result, it is conceivable to speculate that, due to cost-containment policies or limited economic resources, new DAAs will not be affordable soon either. However, while waiting for new molecules, pivotal phase-3 clinical trials on BOC, which included a small sample size of patients with cirrhosis and only a few with both null response and advanced disease [3, 6, 13, 14] , resulted in insufficient data regarding maximum utilization of BOC. Therefore, useful information to guide clinicians in daily practice is needed.
Overall risk to benefit ratio of BOC/P/R treatment in cirrhotic patients was analysed using expanded data from 5 Phase-3 clinical trials [15] . Specifically, this study identified baseline and on-treatment variables (in particular week 8 response) that could help predict response and guide clinical decisions regarding BOC triple therapy for cirrhotic patients, including decisions about discontinuation for futility [15] . As a matter of fact, this post hoc analysis included a carefully selected population with well-compensated disease and, again, a small number of patients with prior null response. Consequently, the results obtained in this study are not fully representative of the real-life population. Some data have indeed been obtained by the CUPIC study [16, 17] , which evaluated triple combination regimens with either telaprevir or BOC in a wider range of treatmentexperienced cirrhotic patients (many of whom would not have qualified for pivotal trials). However, this study included a very small number of prior null responders, as well [16, 17] . In addition, the safety profile reported in the CUPIC study was restricted, mainly due to the considerable number of included patients described as being incompatible with IFN-based regimens [18, 19] .
Here, we report a detailed analysis on the International BOC Name Patient Program (NPP), which was independently carried out in Italian and Spanish qualified Centres. This was the largest cohort of patients with advanced fibrosis/cirrhosis and prior null response ever studied. The information provided enhances the quality of BOC treatment and, therefore, allows better management of these patients while filling the time gap until the arrival of new drugs. By a detailed assessment of efficacy and safety in all different categories of patients, including the week 8 response value, as a predictor of SVR [15] , we were able to assess the number needed to treat (NNT) for each SVR achieved.
PATIENTS AND METHODS
From March 2011 to September 2012, all treatment-experienced patients with HCV genotype 1a or 1b, advanced fibrosis and compensated cirrhosis with or without portal hypertension were enroled for this analysis. The patients were treated in 74 centres in the context of the NPP and each centre included at least three patients.
Baseline recorded data were: gender, age, histology, liver stiffness by FS, oesophageal varices, quantitative HCV-RNA with the Roche COBAS â TaqMan â or Abbot assays with a lower limit of detection of 15 and 12 IU/mL [20, 21] , respectively, HCV genotype and IL28B polymorphism. Clinical and virological assessments were performed every 4 weeks during therapy and at weeks 12 and 24 of the follow-up period. Futility rule was applied by label.
At the time of inclusion, patient disease stage was reevaluated by liver stiffness measurement and by endoscopy. Cirrhosis was defined on the basis of any one of the following criteria: (i) liver biopsy performed prior to Day 1 of the study showing cirrhosis consistent with Metavir score F4 or Ishak F5/6, (ii) presence of oesophageal varices and (iii) fibroScan, performed within 12 calendar months of Day 1 of the study, showing cirrhosis (liver stiffness ≥12.5 kPa) [22, 23] . The diagnosis of advanced liver fibrosis was performed on the basis of any one of the following criteria: (i) liver biopsy, performed within 24 months of Day 1 of the study, showing fibrosis with Metavir score F3 or Ishak F3/4 and (ii) fibroScan, performed within 12 months of Day 1 of the study, showing liver stiffness ≥9.5 and ≤12.5 kPa. In case of disagreement between previous histology (F3) and liver stiffness value, consistent with F4 at time of inclusion, the latter was considered the right one. Written informed consent was obtained from each patient before enrolment. The protocol was carried out in accordance with the Declaration of Helsinki and was approved by local Ethics Committees.
Safety assessment was carried out every 4 weeks with the recording of any AEs and serious AEs (SAEs; including deaths and hospitalizations), and AEs leading to study drug discontinuations. Laboratory assessments focused on anaemia, neutropenia and thrombocytopenia. EPO use and blood transfusions were also recorded. The following parameters were considered to potentially represent hepatic decompensation: onset of ascites, encephalopathy, bleeding from oesophageal varices, jaundice, and sepsis (in the context of declining liver function).
Virological failures and futility rules at week 12 and 24 were used according to the label.
Breakthrough was defined as an HCV-RNA ≥ 1 log increase after an undetectable HCV-RNA. Relapse was defined as the onset of de novo detectable HCV-RNA after EoTR. SVR12 was defined as having undetectable HCV-RNA 12 weeks after completion or discontinuation of therapy.
Statistical analysis
The primary efficacy analysis was conducted on all patients who received at least 1 dose of BOC/P/R, while SVR12 rates (overall and according to fibrosis stage on all patients who received at least 1 dose of P/R during lead-in phase) were also provided. The relationship between baseline and on-treatment factors and SVR was explored using univariate and multivariate logistic regression analyses (MLR). We used a back-wise variable selection, and only variables for which the association remained statistically significant were included in the final multivariable logistic regression model. Stratified MLR analysis was also performed by fibrosis score. Analyses were performed with the SAS software (version 8.2; Cary, NC). All P-values were two-sided. P < 0.05 was considered statistically significant.
RESULTS

Patient accounting and baseline characteristics
Four hundred and sixteen treatment-experienced patients with HCV genotype 1a or 1b with advanced fibrosis or compensated cirrhosis were enroled from 74 centres, which enroled at least three patients in Italy and Spain. Baseline characteristics of the 416 enroled patients (overall and according to administration of BOC after the lead-in phase) are shown in Table 1 . Briefly, 381 (92%) patients received at least one dose of BOC. In the remaining cases (8%), treatment was stopped before starting triple therapy due to poor tolerance to IFN and RBV. Mean age was 57.7 years (range Figure S1 shows the rate of undetectable HCV-RNA at different week points during the full course of treatment and after its discontinuation. Figure 1 shows the overall EoTR, SVR12 and relapse rates, which were 62%, 49% Fig. 1 EoTR, SVR12 and relapse rate overall and according to fibrosis stage. All patients who received at least one dose of BOC included in the study. (Table 2) . Of interest, among 98 patients without a 1-log-decline in HCV-RNA at TW4, 20 had undetectable HCV-RNA and 29 had HCV-RNA < 1000 IU/L at TW8, respectively.
Several factors predicting the achievement of SVR, overall and by F3/F4, were identified with MLR. The factors identified were historical response to P/R (relapser vs partial responder and null responder), fibroScan (1 kPa increase, as a continuous variable), platelet counts (≤100 000/lL) and albumin levels (≤3.5 g/dL), HCV-RNA ≥ 1 log 10 -decline from baseline at TW4, and undetectable HCV-RNA at TW8, which were all independently associated with SVR (Tables 3 and 4) .
In both F3 and F4 patients, HCV-RNA at TW8 ≥ 1000 IU/L (undetectable HCV-RNA as the standard reference) was associated with the lowest likelihood of attaining SVR (95% confidence interval (CI) 10.5-124; risk ratio (RR) 36.1, P < 0.0001, Table 3 ). SVR12, according to TW8 HCV-RNA is illustrated in Fig. 3 . As mentioned, residual viremia >1000 IU/L was associated with high likelihood of not achieving SVR, regardless of whether or not HCV-RNA ≥ 3 log-decline was reached (Fig. 3) . In particular, only 3 of 21 (14%) patients with TW8 HCV-RNA > 1000 IU/mL attained SVR, irrespective of having achieved HCV-RNA ≥ 3 log-decline.
At TW8, 45.2% (159/352) of patients had undetectable HCV-RNA. Baseline characteristics associated with a low likelihood to achieve this result were albumin levels and prior null response (Table S2 ). In addition, female gender, albumin levels and low platelet counts predicted treatment failure in this group of patients, while predictors of SVR in patients with HCV-RNA still detectable at TW8 were Child class A5 vs A6, high albumin levels and high platelet counts, and favourable IL28B CC genotype (Table  S3) . Table S4 shows the rate of SVR among the 159 patients with undetectable HCV-RNA at TW8 according to whether or not they had received a full course of treatment. Interestingly, 102 of 120 (85%) subjects who completed the full course of treatment achieved SVR. Detailed information describes the reasons for early discontinuation of treatment as shown in Table S5 .
NNT calculation
SVR12 and NNT for single SVR stratified by patient characteristics at time of entry, TW8 response and F3/F4 stages are reported in Table 5 .
Safety and tolerability
Overall, 92 patients (24.1%) withdrew from all treatments due to adverse events (Table 6 ). Serious adverse events (i.e. events that resulted in death were life threatening, resulted in persistent or clinically significant disability/incapacity or required hospitalization) occurred in 13.4% (51/381) of all patients. Overall, three patients died (0.8%; 0 in F3, 0 in F4/CP A5 and 3 (7.3%) in F4/ CP A6) at weeks 6, 10 and 28. All deaths occurred in the F4 group of 289 patients (1%) compared to 0 deaths in the group of 127 F3 patients. The cause of death was attributable, in all cases, to multiple organ failure following the onset of severe infection and generalized sepsis (Table 6) . Overall, 11 patients (2.9%) had hepatic decompensation, and all episodes were observed in cirrhotic patients (3.8%). The frequency of serious adverse events was higher in patients with more advanced disease and in the Spanish cohort (Table S6) . At MLR, Metavir F4, NNT, number needed to treat; None of the seven patients with both low albumin and low platelet counts had SVR.
© 2014 John Wiley & Sons Ltd liver stiffness ≥12.5 kPa and Child class A6 were independently associated with the occurrence of SAEs (Table 7) . Two other strong predictors of SAEs during treatment with BOC were also lower platelet counts and lower albumin levels at baseline with an OR of 2.39 (95% CI: 1.12-5.10) and of 3.42 (95% CI: 1.45-8.08), respectively (Table 7) . Details on hospitalization are summarized in Table S7 . Approximately 70% of patients had bone marrow toxicity (Table 6 ). Table S8 shows the proportion of patients who required reduction of IFN, RBV or both. RBV dose reduction was associated with higher SVR rates (P < 0.003), while IFN reduction had no effect on SVR. In multivariate analysis, female gender, older age (>60 years) and low platelet counts were associated with increased risk of haematological adverse events (Table 7) .
Resistance-associated variants
NS3 genotype resistance testing by population sequencing was performed in 15 patients failing triple therapy with BOC (3 = GT-1a, 11 = GT-1b and 1 = GT-1 g) and in 4 patients with early treatment discontinuation for adverse events (1 = GT-1a and 3 = GT-1b) (Table S9 ). Population sequencing of the viral protease was performed after a median (IQR) of 5 (À5;34) days from the time of treatment discontinuation or virological failure. Upon sequencing, HCV-RNA had median (IQR) values of 5.1 (3.8-5.0) log IU/mL, ranging from 280 to 3 002 138 IU/mL. Overall, at least one resistance-associated variant (RAV) was found in 12 of 15 patients analysed at the time of virological failure. In particular, in all patients that showed viral breakthrough during treatment (N = 3) or relapse after reaching the end of treatment (N = 4), the increase of viremia after achieving undetectable HCV-RNA was associated with RAVs occurrence (Table S9) . Conversely, among the eight patients who discontinued treatment in accordance with BOC stopping rules, the de novo development of RAVs was exclusively observed in the 2 patients in whom the interruption was delayed by investigator decision and in 1 GT-1a patient presenting at baseline with the NS3 mutation Q80K. The remaining 5 patients who discontinued treatment after 12 weeks for virological failure did not show de novo development of RAVs. One of them was however infected by GT-1 g [24] . The characteristics of de novo RAV mutations within the 10 patients experiencing virological failure is described in Table S9 . Among the 4 patients who prematurely discontinued treatment due to adverse events, 1 who delayed the discontinuation of treatment despite the futility rule showed de novo development of RAVs (R155K).
DISCUSSION
Boceprevir, in combination with P/R, was launched in September 2010. However, in several countries, it is still not available. Since then, with the exception of the US and few European countries, all other nations permitted this treatment only for patients with more advanced liver disease, mainly due to cost-containment measures. This limitation is expected to be maintained for at least the next 2 years in the vast majority of the world. In addition, it is well known that achieving an SVR reduces the risk of HCC, decompensation, and all-cause mortality in patients with cirrhosis [25] [26] [27] . Therefore, deferring access to therapy in these patients while waiting for all oral IFN-free regimens might not be an option. However, the safety concern reported in the CUPIC study [17] , especially for patients with severe portal hypertension and deteriorated liver function as well as lacking data in patients with previous null response to P/R, suggest that additional, reliable information to optimize BOC-based treatment in daily practice is needed. Here, we show that, 50% of all F4 patients treated with BOC/P/R can achieve an SVR. SVR rates were particularly high (69%) in patients with undetectable HCV-RNA at TW8, as previously reported in a smaller number of patients with such characteristics [18] ; these patients accounted for almost half of all treated cirrhotic populations. Furthermore, F3 patients with undetectable viral load at TW8 achieved higher SVR rates (80%). The reason why the rate of SVR in patients with F4 is lower, when compared to F3 subjects, is easily explained by the higher relapse rate observed in this latter group of patients. Additional information provided by this study is that in patients with undetectable HCV-RNA at TW8 who tolerated a full course of therapy, SVR was extremely high (86%) and this finding was observed in more than two-third of this group of patients. Moreover, as there was no discontinuation related to virological breakthrough in this group of subjects, we may assume that the emergence of escape mutants was absent or very low. Previously, it was reported that SVR was more likely in patients with advanced fibrosis/cirrhosis who had an HCV-RNA decline ≥1.0 log at week 4 (end of the lead-in phase with P/R) [18] . However, although this result was confirmed in our analysis, we found that approximately 50% of patients with <1 log-decline at TW4 achieved undetectable HCV-RNA or <1000 IU/L at TW8. This data supports the decision to start BOC therapy after the lead-in phase, to avoid missing several SVRs in this poor IFN-sensitive population.
Irrespective of the fibrosis stage, HCV-RNA ≥ 1000 IU/L at TW8 was associated with a negligible rate of SVR (8%, NPV = 92%). In agreement with the FDA and the European Commission (EC), which approved a revision of the BOC Prescribing Information, (i.e. a futility rule to stop therapy with BOC/P/R in all patients if TW8 HCV-RNA levels are ≥1000 IU per mL was added), our results provide a solid validation in support of this decision.
Additional predictors of SVR for F4 patients in the MLR analysis included male gender, prior null response, low albumin levels and low platelet counts. Supplemen- tary information emerging from the study was that liver stiffness, the value of which was found to be associated with disease outcome [28] , paralleled some well-established surrogate markers of disease severity and portal hypertension (i.e. Child class, platelet counts, and oesophageal varices) in predicting SVR. Consequently, this variable may be proposed, as a useful tool to identify the subgroup of patients not eligible for therapy with firstgeneration PIs.
Although the clinical characteristics of F4 patients treated with BOC/P/R in the French Early Access Programme were similar to those of patients in our study (median age was 56.8 vs 57.7 years, proportion of male patients was 67.9% vs 69.5%), there were some differences between the two cohorts. First of all, null responders were originally excluded from the CUPIC study and, ultimately, 8% of these subjects were enroled. Moreover, both mean baseline platelet counts and serum albumin levels were lower in the BOC-CUPIC arm (144 000/lL vs 165 000/lL and 4.8 vs 4.0 g/dL, respectively) compared to patients enroled in our study, and NPP included 2.4% (vs 8.3% in CUPIC) of patients with concomitant low baseline albumin levels and platelet counts. Finally, the frequency of infection with HCV genotype 1a was different (41% vs 22.4%). The proportion of patients with oesophageal varices was also similar (37.6% vs 42%), but it should be noted that an upper gastrointestinal endoscopy was performed in only 51.4% of patients of the CUPIC population treated with BOC.
Despite these discrepancies, in agreement with the CU-PIC study, we confirmed that the concurrent presence of low albumin levels and platelet counts at baseline was a strong predictor of poor response. Similarly, to the French study, our survey showed that poor TW8 response (i.e. HCV-RNA <3 log-decline compared to baseline) is associated with a low likelihood of SVR. Therefore, we may speculate that the two studies mutually validated themselves and may be considered complementary in enhancing the knowledge regarding this type of patients.
In summary, the present study provides the most detailed analysis ever carried out in the largest group of patients with advanced liver disease treated with BOC. The attained results enable clinicians to evaluate, in each single category of patients, predictors of both SVR (thus permitting the calculation of the NNT) and severe complications (both liver and haematological-related). The NNT in patients with undetectable HCV-RNA at TW8 is extremely favourable regardless of all negative baseline predictors. Moreover, using this new TW8 futility rule, which our study strongly validates, EPO and blood transfusions may be spared, and the hospitalization rate may be reduced, thus lowering the total cost of therapy. Finally, this may be a way for clinicians to not deny BOC triple therapy 'a priori' to all IFN-eligible patients, and thus safely prevent exposure to an ineffective treatment in patients with a potential high rate of adverse events.
In conclusion, this analysis assessed potential benefits and risks of BOC treatment in a wide range of patients with advanced liver disease. Using a simple combination of baseline and on-treatment predictors, clinicians may easily identify patients with a high likelihood of achieving SVR and those at risk for severe complications. To fill the time gap until all oral DAAs become available, an eight-week BOC-based treatment may be proposed as a right option to assess tolerability and likelihood of success of this therapy in cirrhotic patients whose characteristics make them eligible for IFN-based regimens.
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